SCHEMBL3979224

SCHEMBL3979224

Brc1cnc(Oc2ccc(I)cc2)nc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 5/20 0.43
FFAR1 O14842 1/20 0.43
TUBB4A P04350 2/20 0.40
TUBB P07437 2/20 0.40
TUBA3C P0DPH7 2/20 0.40
TUBA1B P68363 2/20 0.40
TUBA4A P68366 2/20 0.40
TUBB4B P68371 2/20 0.40
TUBB3 Q13509 2/20 0.40
TUBB2A Q13885 2/20 0.40
TUBB8 Q3ZCM7 2/20 0.40
TUBA3E Q6PEY2 2/20 0.40
TUBA1A Q71U36 2/20 0.40
TUBA1C Q9BQE3 2/20 0.40
TUBB6 Q9BUF5 2/20 0.40
TUBB2B Q9BVA1 2/20 0.40
TUBB1 Q9H4B7 2/20 0.40
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
APAF1 O14727 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22404982 0.80 NPSR1 (0.57) FFAR1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL11080118 0.80 MEN1 (0.50) FFAR1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL24156362 0.80 MEN1 (0.44) FFAR1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL3977514 0.80 ALDH1A1 (0.57) FFAR1MEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL11153430 0.80 MEN1 (0.62) FFAR1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL2313930 0.79 MEN1 (0.55) FFAR1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL18554989 0.78 FFAR1 (0.40) FFAR1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL806523 0.77 MEN1 (0.63) APPMEN1KMT2AAPAF1SMN1; SMN2
SCHEMBL4094148 0.76 ALDH1A1 (0.43) FFAR1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4374065 0.76 THRB (0.47) FFAR1TUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291971-A1 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION WYETH (US) 2009-11-26 US disclosed
US-20090291971-A1 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION WYETH (US) 2009-11-26 US disclosed
US-20090291971-A1 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION WYETH (US) 2009-11-26 US disclosed
WO-2009058937-A2 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION WYETH (US) 2009-05-07 WO disclosed
WO-2009058937-A2 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION WYETH (US) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291971-A1 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION AHR, MALT1, ABL1 APP 3674/4885FFAR1 2095/4885TUBB4A 2475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.